The 5th edition of WHO Classification of Endocrine and Neuroendocrine Tumors (2022) introduced many significant changes relevant to endocrine daily practice. In this newsletter, we summarize the notable changes to the adrenal cortex based on the 5th edition of the WHO classification [1].
The 5th edition WHO Classification of Urinary and Male Genital Tumours (2022) introduced many significant changes relevant to urologic daily practice, mainly to renal tumors which was covered in the What’s New newsletter in September 2022. In this newsletter, we summarize the notable changes to bladder, prostate, testis, and penis based on the 5th edition of the WHO.
Citations
Citations to this article as recorded by
Predicting variant histology in bladder cancer: the role of multiparametric MRI and vesical imaging-reporting and data system (VI-RADS) Serdar Aslan, Merve Nur Tasdemir, Ertugrul Cakir, Ural Oguz, Birgul Tok Abdominal Radiology.2025;[Epub] CrossRef
Pictorial review of multiparametric MRI in bladder urothelial carcinoma with variant histology: pearls and pitfalls Yuki Arita, Sungmin Woo, Thomas C. Kwee, Keisuke Shigeta, Ryo Ueda, Sunny Nalavenkata, Hiromi Edo, Kosuke Miyai, Jeeban Das, Pamela I. Causa Andrieu, Hebert Alberto Vargas Abdominal Radiology.2024; 49(8): 2797. CrossRef
Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series Marco Finati, Antonio Fanelli, Francesco Cinelli, Nicola Schiavone, Ugo Giovanni Falagario, Anna Ricapito, Nicola d’Altilia, Richard Naspro, Angelo Porreca, Felice Crocetto, Biagio Barone, Ciro Imbimbo, Carlo Bettocchi, Francesca Sanguedolce, Luigi Cormio World Journal of Urology.2024;[Epub] CrossRef
The 5th edition WHO Classification of Urinary and Male Genital Tumours (2022) introduces significant changes relevant to daily practice, especially in the completely restructured renal cell tumor chapters. Herein we highlight the most important diagnostic updates of known kidney tumor types, new and molecularly defined entities and emerging/provisional entities.
Citations
Citations to this article as recorded by
Convolutional neural networks for the differentiation between benign and malignant renal tumors with a multicenter international computed tomography dataset Michail E. Klontzas, Georgios Kalarakis, Emmanouil Koltsakis, Thomas Papathomas, Apostolos H. Karantanas, Antonios Tzortzakakis Insights into Imaging.2024;[Epub] CrossRef
PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis Silviu Constantin Badoiu, Maria Greabu, Daniela Miricescu, Iulia-Ioana Stanescu-Spinu, Radu Ilinca, Daniela Gabriela Balan, Andra-Elena Balcangiu-Stroescu, Doina-Andrada Mihai, Ileana Adela Vacaroiu, Constantin Stefani, Viorel Jinga International Journal of Molecular Sciences.2023; 24(9): 8391. CrossRef
Machine Learning Integrating 99mTc Sestamibi SPECT/CT and Radiomics Data Achieves Optimal Characterization of Renal Oncocytic Tumors Michail E. Klontzas, Emmanouil Koltsakis, Georgios Kalarakis, Kiril Trpkov, Thomas Papathomas, Apostolos H. Karantanas, Antonios Tzortzakakis Cancers.2023; 15(14): 3553. CrossRef
Serum Oxidative and Nitrosative Stress Markers in Clear Cell Renal Cell Carcinoma Sabina Galiniak, Marek Biesiadecki, Mateusz Mołoń, Patrycja Olech, Krzysztof Balawender Cancers.2023; 15(15): 3995. CrossRef
Redefining Renal Cell Carcinoma: A Molecular Perspective on Classification and Clinical Implications Arjun Athreya Raghavan, Ian W Gibson, Robert Wightman, Piotr Czaykowski, Jeffrey Graham European Medical Journal.2023; : 116. CrossRef